Literature DB >> 1496814

Bioavailability of ivermectin administered orally to dogs.

C P Daurio1, E N Cheung, A R Jeffcoat, B J Skelly.   

Abstract

The bioavailability of three formulations of ivermectin was determined following oral administration to dogs. The average peak plasma level (Cmax) of ivermectin administered in the standard tablet formulation at 6 and 100 micrograms/kg of body weight was 2.97 and 44.31 ng/g, respectively. This suggest dose-dependent pharmacokinetics. Cmax and total ivermectin bioavailability, as assessed from the area under the plasma curve (AUC), were similar between two tablet formulations of ivermectin administered at 100 micrograms/kg. Furthermore, Cmax was similar following administration of radiolabelled ivermectin at 6 micrograms/kg in either a beef-based chewable formulation or in the standard tablet formulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1496814     DOI: 10.1007/bf01839009

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  4 in total

1.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

2.  Determination of ivermectin by fluorescence derivatization.

Authors:  J D Stong
Journal:  Anal Chem       Date:  1987-01-15       Impact factor: 6.986

3.  Determination of 22,23-dihydroavermectin B1a in dog plasma using solid-phase extraction and high-performance liquid chromatography.

Authors:  K Kojima; K Yamamoto; Y Nakanishi; H Katae
Journal:  J Chromatogr       Date:  1987-01-23

4.  Efficacy of ivermectin chewable tablets and two new ivermectin tablet formulations against Dirofilaria immitis larvae in dogs.

Authors:  A J Paul; K S Todd; K E Acre; R E Plue; D H Wallace; R A French; M A Wallig
Journal:  Am J Vet Res       Date:  1991-11       Impact factor: 1.156

  4 in total
  7 in total

Review 1.  How do the macrocyclic lactones kill filarial nematode larvae?

Authors:  Adrian J Wolstenholme; Mary J Maclean; Ruby Coates; Ciaran J McCoy; Barbara J Reaves
Journal:  Invert Neurosci       Date:  2016-06-09

Review 2.  Heartworm disease - Overview, intervention, and industry perspective.

Authors:  Sandra Noack; John Harrington; Douglas S Carithers; Ronald Kaminsky; Paul M Selzer
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2021-04-27       Impact factor: 4.077

3.  Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.

Authors:  Nicole Scherr; Gerd Pluschke; Charles J Thompson; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2015-08-13

4.  Efficacy of 10% imidacloprid + 2.5% moxidectin topical solution (Advantage Multi® for Dogs) for the prevention of heartworm disease and infection all month long.

Authors:  Dwight D Bowman; Cameon M Ohmes; Joseph A Hostetler; Daniel J Keil; Terry L Settje; Samuel D Charles
Journal:  Parasit Vectors       Date:  2017-11-09       Impact factor: 3.876

5.  Differential ABC transporter gene expression in adult Dirofilaria immitis males and females following in vitro treatment with ivermectin, doxycycline or a combination of both.

Authors:  Chiara Lucchetti; Marco Genchi; Luigi Venco; Alessandro Menozzi; Paolo Serventi; Simone Bertini; Chiara Bazzocchi; Laura Helen Kramer; Alice Vismarra
Journal:  Parasit Vectors       Date:  2019-08-13       Impact factor: 3.876

6.  Development of an in vitro bioassay for measuring susceptibility to macrocyclic lactone anthelmintics in Dirofilaria immitis.

Authors:  Christopher C Evans; Andrew R Moorhead; Bobby E Storey; Adrian J Wolstenholme; Ray M Kaplan
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-06-06       Impact factor: 4.077

7.  Protection of dogs against canine heartworm infection 28 days after four monthly treatments with Advantage Multi® for Dogs.

Authors:  Dwight D Bowman; Alyssa R Grazette; Chris Basel; Yingying Wang; Joseph A Hostetler
Journal:  Parasit Vectors       Date:  2016-01-08       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.